As the post-pandemic world of work continues to evolve, so do recruiters’ strategies and tools for finding and engaging top talent. In 2023, we are seeing these seven trends:1. Employer branding is becoming an increasingly important factor in the recruitment…
HOME > COMMENTARY
COMMENTARY
-
COMMENTARY/Preparations for New OTC Drug Marketing System Enter Final Stage
March 3, 2008
-
COMMENTARY/Japan Needs to Create Attractive "Stadium for Drug Discovery" and Invite Top-Level Players
February 25, 2008
-
COMMENTARY/Revision of Medical Fees May Increase Use of Drugs for Stroke, Mental Illnesses, Cancer
February 11, 2008
-
Current New Drug Development in the Japanese Pharmaceutical Industry(2)
February 11, 2008
-
Current New Drug Development in the Japanese Pharmaceutical Industry(1)
February 11, 2008
-
COMMENTARY/Generic Makers Increase Investment, but Will Consumption Really Increase as Gov't Hopes?
February 4, 2008
-
COMMENTARY/Full-Scale M&As Imminent among Dispensing Pharmacy Chains
January 28, 2008
-
COMMENTARY/Full-Scale M&As Imminent among Dispensing Pharmacy Chains
January 28, 2008
-
OPINION/The East versus West Dilemma
January 28, 2008
-
No More Need for MRs? -A Hell beyond the 2010 Crisis?-
January 14, 2008
-
COMMENTARY/Year 2007 in Retrospect
December 24, 2007
-
COMMENTARY/Appreciation Mixed with Concern: Proposed NHI Pricing Reform
December 17, 2007
-
COMMENTARY/Fight over Medical Fee/NHI Price Revision Rates Begin
December 3, 2007
-
COMMENTARY:Korosho Must Explain Its "Primary Doctor" System Proposal in Detail
October 1, 2007
-
Gakkai, Specialty Certification and Industry by Mark Colby
September 10, 2007
-
COMENTARY:Korosho Required to Cut \220 Bil. in Social Security Spending
September 3, 2007
-
COMMENTARY/NHI Drug Pricing System Reform: Many Similarities in Proposals from JPMA, PhRMA, EFPIA
August 27, 2007
-
COMMENTARY/Range of Drugs Re-priced due to Expansion of Market May Be Expanded
July 23, 2007
-
COMMENTARY/Market for Osteoporosis Drugs Booms
July 9, 2007
-
COMMENTARY/Pressure Mounting on Long-Listed Original Drugs
July 9, 2007
ページ
Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…